Cargando…
COVID‐19 mRNA vaccines and myopericarditis
Globally, vaccination against COVID‐19 has prevented countless infections, hospitalisations and death and represents the most successful intervention in combating the pandemic caused by SARS‐CoV‐2 infection. Utilisation of existing mRNA vaccine technology has allowed for rapid development of highly...
Autores principales: | Gnanenthiran, Sonali R., Limaye, Sandhya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111655/ https://www.ncbi.nlm.nih.gov/pubmed/35289493 http://dx.doi.org/10.1111/imj.15748 |
Ejemplares similares
-
A Case of Myopericarditis After the Second Dose of mRNA COVID-19
Vaccine in a Patient With a History of Myopericarditis
por: Fujibayashi, Kosuke, et al.
Publicado: (2022) -
Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents
por: Long, Sarah S.
Publicado: (2021) -
Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
por: Hajra, Adrija, et al.
Publicado: (2021) -
Recurrence of Myopericarditis Following mRNA COVID-19 Vaccination in a Male Adolescent
por: Umei, Tomohiko C., et al.
Publicado: (2021) -
Myopericarditis After mRNA COVID-19 Vaccine in a Patient With Recent History of COVID-19
por: Elhouderi, Eiman, et al.
Publicado: (2022)